Back

Current status and factors associated with SGLT2i and MRA utilization for hospitalized heart failure with mildly reduced or preserved ejection fraction : a survey from JROAD-DPC database

28 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: integrating therapies and education Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Yoko Nakao

Kyoto University, Kyoto (Japan)

6 More presentations in this session

Presentation thumbnail
Additive benefits of combination ARNI and SGLT2 inhibitor therapy in real-world heart failure: a propensity-weighted analysis of 11,483 asian patients
Doctor P. Amornritvanich (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Low blood pressure and the effect of SGLT2 inhibitors in heart failure with reduced ejection fraction: data from the China Cardiovascular Association Database-Heart Failure Center Registry
Doctor W. Jin (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Hyperkalemia and its outcome implications in patients with heart failure with reduced ejection fraction: results from a single-center cohort
Doctor M. Mantovani (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy of sodium–glucose cotransporter 2 inhibitors in heart failure patients with low body mass index
Doctor K. Nakamoto (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Outcomes of sacubitril/valsartan plus SGLT2 inhibitors versus SGLT2 inhibitors in heart failure with reduced ejection fraction: a propensity-matched real-world analysis
Doctor O. Alameen (Doha, QA)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: integrating therapies and education

The Event

Event poster

ESC Congress 2026

28 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Contemporary use of SGLT2i therapy among patients hospitalized for heart failure with reduced ejection fraction in the United States
22 May 2023
thumbnail
Congress Presentation
The mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction
29 June 2021
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
31 August 2024
thumbnail
Congress Presentation
Optimized medical therapy in non-ischemic heart failure-How about real life?
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources